An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (APOLLOE4)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Sponsor: Alzheon Inc.
A PHASE3 clinical study on Early Alzheimer's Disease, this trial is completed. The trial is conducted by Alzheon Inc. and has accumulated 18 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
18 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 13 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Mar 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alzheon Inc.
- National Institute on Aging (NIA)
For direct contact, visit the study record on ClinicalTrials.gov .